CFTR and cystic fibrosis: The drug effect was stronger on sputum biochemistry with a decrease in peptides, amino acids and kynurenine metabolism; these findings suggest that ETI therapy and possibly other CFTR modulators [77] might “reshape microbiome niche space in CF mucus” by decreasing the availability of peptides and amino acids, an effect that could have clinical implications for the treatment of lung infections.